Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Moelis & Company on Amgen’s $1.16 Billion Acquisition of Micromet

February 2, 2012

NEW YORK, February 2, 2012 — Covington & Burling represented Moelis & Company, financial advisor to Amgen, in its cash acquisition of Micromet, Inc. in a deal valued at approximately $1.16 billion.

The acquisition, reported on Jan. 26, includes blinatumomab, a Bispecific T cell Engager antibody in Phase 2 clinical development for acute lymphoblastic leukemia. Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma, and could have applications in other hematologic malignancies.

Moelis is a global investment bank that provides financial advisory, capital raising and asset management services to a broad client base including corporations, institutions and governments. Amgen discovers, develops, manufactures and delivers innovative human therapeutics. Micromet is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer.

The New York-based Covington corporate team was led by partner J. D. Weinberg, with associate Richard Kruger.

Share this article: